British boy receives lifesaving surgery for rare cancer in Kansas
Alex Goodwin, from Rugby, England, was diagnosed with Ewing's Sarcoma last year after months of agony in his joints and muscles. (Source: the Mail online | Health)
Source: the Mail online | Health - January 13, 2017 Category: Consumer Health News Source Type: news
British boy, 9, receives lifesaving surgery for rare cancer in Kansas after being dismissed by UK doctors for five months - even though he couldn't walk
Alex Goodwin, from Rugby, England, was diagnosed with Ewing's Sarcoma last year after months of agony in his joints and muscles. (Source: the Mail online | Health)
Source: the Mail online | Health - January 12, 2017 Category: Consumer Health News Source Type: news
Top Sarcoma News in 2016
In this slide show we highlight some of the top news on sarcoma in 2016, including the first frontline FDA approval in 40 years, and studies on imaging in Ewing sarcoma, maintenance chemotherapy in osteosarcoma, and more. (Source: CancerNetwork)
Source: CancerNetwork - December 14, 2016 Category: Cancer & Oncology Authors: Cancer Network Editors Tags: Conferences/Sarcoma Year In Review 2016 Source Type: news
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
(IDIBELL-Bellvitge Biomedical Research Institute) IDIBELL researchers describe the Ewing's sarcoma (ES) methylation profile for the first time.The methylation profile unveils the potential of the PTRF gene as a prognostic marker of the disease.The reestablishment of PTRF expression could serve as a therapeutic option in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2016 Category: Cancer & Oncology Source Type: news
The dark side of 'junk' DNA
(UNC Lineberger Comprehensive Cancer Center) Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center report in the journal Cell Reports that certain short, repetitive sequences of DNA, or 'junk,' play an important role in the development of Ewing sarcoma, a rare bone and soft tissue cancer that occurs most commonly in children and adolescents. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2016 Category: Cancer & Oncology Source Type: news
Cancer or no cancer — Carlie will sing!
Her voice at first sings softly, then gradually gains intensity and rises to a crescendo as she belts out the refrain of a tune she and her dad co-wrote: “You’re not standing alone!”
Fifteen-year-old Carlie Gonzalez has been singing and making music for as long as she can remember. But these days singing has new meaning. After eight months of intensive treatment for Ewing sarcoma, a type of bone cancer, her powerful voice is also a symbol of her physical and emotional strength.
Three weeks after school started in September 2015, Carlie began to feel a pain in her collarbone. Since she also played volleyball, when an ...
Source: Thrive, Children's Hospital Boston - September 1, 2016 Category: Pediatrics Authors: Linda Watts Tags: Our Patients’ Stories Dana-Farber/Boston Children's Cancer and Blood Disorders Center Ewing Sarcoma Source Type: news
Oncternal Therapeutics begins dosing in Phase I trial of TK216 to treat Ewing sarcoma
US-based clinical-stage biotechnology company Oncternal Therapeutics has begun dosing patients in its Phase I clinical trial of TK216 to treat Ewing sarcoma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 31, 2016 Category: Pharmaceuticals Source Type: news
A new animal model to understand metastasis in sarcomas
Researchers have developed a modified version of an orthotopic model to recreate the metastatic steps in Ewing sarcoma, the second most common bone tumor in children and adolescents. This new model may become a valuable experimental tool to analyze metastatic potential in different kinds of sarcomas. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 30, 2016 Category: Science Source Type: news
A new animal model to understand metastasis in sarcomas
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers from IDIBELL have developed a modified version of an orthotopic model to recreate the metastatic steps in Ewing sarcoma, the second most common bone tumor in children and adolescents. This new model may become a valuable experimental tool to analyze metastatic potential in different kinds of sarcomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2016 Category: Cancer & Oncology Source Type: news
Better Imaging Method for Ewing Sarcoma Response Assessment
Functional imaging using FDG-positron emission tomography (FDG-PET) was able to predict response to treatment in Ewing sarcoma patients, and was superior to other anatomic imaging criteria. (Source: CancerNetwork)
Source: CancerNetwork - August 29, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news
What Are The Most Common Pediatric Cancers?
Discussion
Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for <1% of all cancers yearly in the US. Approximately 10,000 US children under age 15 will be diagnosed with cancer in 2016. More than 80% of those children will survive more than 5 years because of advances in direct cancer treatment and treatment of its complications. Survival rates depend on a number of factors including the type of cancer and location. Despite these good numbers, about 1250 children in the US die yearly from pediatric cancer. After accidents, childhood cancer, suicid...
Source: PediatricEducation.org - July 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Pharma company to relocate to Houston following CPRIT grant
Salt Lake City-based Salarius Pharmaceuticals LLC will relocate to Houston following an $18.69 million grant from the Cancer Prevention and Research Institute of Texas.
CPRIT awarded Salarius and Pelican Therapeutics two grants totaling nearly $34 million to recruit both of the companies to the Lone Star State. Pelican will be located in Austin, according to a statement.
Salarius is developing a drug that will target Ewings Sarcoma, a pediatric bone cancer with no targeted therapies. Currently… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 19, 2016 Category: Biotechnology Authors: Joe Martin Source Type: news
Scientists uncover novel therapeutic targets and candidate biomarkers in childhood cancers
(Write Science Right) Brazilian scientists have obtained evidence suggesting that neurotrophins, which are well-known signaling molecules in normal brain development and function, may be useful biomarkers and therapeutic targets in childhood cancers. Blockade of the receptors that mediate neurotrophin signaling, namely TrkA and TrkB, have been shown to produce anticancer effects in both Ewing sarcoma and medulloblastoma. Additionally, levels of a neurotrophin have been associated with leukemia prognosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 18, 2016 Category: Cancer & Oncology Source Type: news
Ewing Sarcoma: New compounds may aid in development of targeted therapies for a rare pediatric cancer
Two recently discovered compounds have shown promise in preclinical studies for treating Ewing sarcoma, a rare cancer that predominantly affects children and adolescents. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 30, 2016 Category: Science Source Type: news
New compounds may aid in development of targeted therapies for a rare pediatric cancer
(Van Andel Research Institute) Two recently discovered compounds have shown promise in preclinical studies for treating Ewing sarcoma, a rare cancer that predominantly affects children and adolescents. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 30, 2016 Category: Cancer & Oncology Source Type: news
